Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RXI-109 in Hypertrophic Scar Revision
NCT02246465Phase 2Unknown
- Sponsor
- Phio Pharmaceuticals
- Start
- Jul 2014
- Primary completion
- Dec 2017
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 2
01
Overview
A Phase 2 trial of CTGF siRNA in Hypertrophic Scar (HS), sponsored by Phio Pharmaceuticals. Status: unknown.
02
Drugs
CTGF siRNA
03
Conditions
Hypertrophic Scar (HS)
Beyond the preview
Go deeper on NCT02246465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02246465.